TRANSCELL research project invested in the development of innovative cell therapies in order to tackle the current therapeutic complications of allo-HSCT.
The produced cell products include: i) non-genetic modified T lymphocytes that aim 4 viruses (CMV, EBV, BK, ADV) and Aspergillus fungus (penta-STs), considered as the most common life-threatening factors for transplant patients, and ii) regulatory T lymphocytes with immunomodulatory function (iG-Tregs) that suppress the allo-reactivity observed Graft vs Host Disease (GvHD).
The TRANSCELL database hosts the total T cell receptor clonotypes that were recognized by the sequencing of the receptor’s beta chain gene rearrangements.